IntelWATT aims to develop innovative, cost efficient, smart separation technologies applied in energy and water intensive industries. The goal of the project is to demonstrate 3 TRL7 case studies that will achieve water preservation along with energy production and material recovery. The proposed solutions will also target at zero liquid discharge while implementing maximum water reuse. Tailor made sensors and automated decision making mechanisms will optimize the process conditions in real time. The case studies will be implemented in crucial EU and global industrial applications such as electricity production, mining and metal plating. -Case study 1:Demonstration prototype for CTBD treatment. The development of efficient, cost effective, smart solutions for water management in a thermoelectric power plant, aiming at minimization of the cooling tower blow down (>99% recovery) trough developing a pilot unit of 100 m3/day treatment capacity installed in the premise of PPC’s unit V (natural gas combined circle facility, Megalopolis, Greece) based on a closed loop, near zero liquid discharge approach. -Case study 2: Demonstration of a symbiotic concept between industries: sustainable production of energy and water. In this context, an integrated pilot unit (100 m3/day) comprised by Reverse Electrodialysis (RED) and solar powered membrane distillation (MD) systems. -Case study 3: The application of a novel, hybrid high recovery RO (HRRO) / Ion exchange (IX) resin prototype will demonstrate the recovery of valuable electrolytes and fresh water preservation in a plastic electroplating facility. The process is aiming towards recovering up to 95 % of Chromium and Copper and 50% of Nickel, while preserving 65% of fresh water. Implement smart sensor technology for online monitoring, real time process adaptation and deep learning, with customizable intelligent industrial process software module based on an agnostic protocol connectivity cloud infrastructure.

Chronic obstructive pulmonary disease (COPD) is a highly prevalent chronic condition. While COPD is a lung disease, it is mainly the exacerbations and extrapulmonary comorbidities which affect the quality of life, health care costs, and prognosis. The optimal COPD treatment needs to focus on both the characteristics and consequences of the lung disease itself and the diagnosis and treatment of comorbidities. While the severity of lung function impairment is routinely assessed, the exacerbations, the associated comorbidities and limitations in daily life are still significantly underestimated. A personalized approach to COPD management is needed to specifically address the disease, prevent exacerbations, and mitigate its comorbidities to obtain a positive impact on patient health and quality of life. TOLIFE will clinically validate an artificial intelligence (AI) solution to process daily life patient data captured by unobtrusive sensors to enable optimised personalised treatment, assessment of health outcomes and improved quality of life in COPD patients. The TOLIFE approach to COPD management, targeted to predict and mitigate exacerbations and continuously assess the health outcomes, has the potential to reduce mortality, improve health related quality of life and reduce the healthcare costs. TOLIFE will develop and clinically validate an AI-based platform for the early prediction of exacerbations and assessment of the health outcomes. Prediction of exacerbations and assessment of health outcomes will be exploited by clinicians through a patient management tool to perform early and personalized treatment. TOLIFE platform will inform through a disease information tool the patient and caregivers about the patient's health status, the specific treatment plan and lifestyle indications. Two clinical studies will be implemented, one to collect data for AI-tools development and the other to validate the effectiveness of TOLIFE to reduce the risk of exacerbations.